Please amend page 29 line 1 as follows:

#### Claims What is claimed is:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

### 1. (Original) A compound of formula (I):

$$Z_{1}-W_{1}-CH_{2} \qquad NH_{2}$$

wherein

R<sup>2</sup> is

wherein b is an integer of from 0 to 10;

R<sup>3</sup> is a C<sub>1-4</sub> alkylene or C<sub>2-4</sub> alkenylene bridge;

 $W_1$  is absent or represents a spacer moiety which is a  $C_{1-30}$  hydrocarbyl group optionally including 1 to 10 heteroatoms selected from oxygen, nitrogen, and sulphur, and is

preferentially derived from glutaric and/or succinic acid and/or a polyethyleneglycol based unit and/or a unit of Formula :

 $Z_1$  is an antineoplastic agent, a chelating agent or a reporter moiety.

- 2. (Original) A compound of formula (I) according to claim 1, wherein  $Z_1$  is a reporter moiety comprising a radionuclide.
- 3. (Original) A compound of formula (Ia):

wherein

R<sup>1</sup> is either a bond or is

wherein a is an integer of from 1 to 30;

R<sup>2</sup> is

wherein b is an integer of from 0 to 10;

 $R^3$  is a  $C_{1-4}$  alkylene or  $C_{2-4}$  alkenylene bridge;

the Linker is a  $C_{1-30}$  hydrocarbyl group optionally including 1 to 10 heteroatoms.

4. (Original) A compound of formula (Ia) according to claim 3 in which:

R<sup>3</sup> is C<sub>1-4</sub> alkylene;

a is an integer of from 1 to 10; and

b is 1.

5. (Currently amended) A compound of formula (Ia) according to claim 3 or 4 in which:

R<sup>3</sup> is-CH<sub>2</sub>-; and

a is 5.

6. (Currently amended) A compound of formula (Ia) according to any of claims 3 to 5 claim 3 in which the Linker is selected from (II), (III) and (IV):

$$-(CH_2CH_2O)_n-(CH_2)_m$$
 (II)

$$-(CH2)p-$$
 (III)

$$-(CH_2)_q \longrightarrow N(CH_2)_r \longrightarrow (IV)$$

wherein:

n is an integer of 1 to 20;

m is an integer of 1 to 10; p is an integer of 1 to 20; q is an integer of 0 to 4; r is an integer of 1 to 10.

7. (Currently amended) A compound of formula (Ia) according to any of claims 3 to 6 claim 3 which is:

- 8. (Currently amended) A compound of formula (I) or (Ia) according to any of claims 1 to 7 claim 1 for use in medicine, particularly in the *in vivo* diagnosis or imaging, for example by PET, of a disease or condition associated with angiogenesis.
- 9. (Currently amended) A method for *in vivo* diagnosis or imaging of a disease or condition associated with angiogenesis which comprises the step of administering a compound of formula (I) or (Ia) according to any of claims 1 to 7 claim 1 to a human or animal body, followed by generation of an image, suitably a PET image, of part or all of said body
- 10. (Currently amended) A radiopharmaceutical formulation comprising a compound of formula (I) or (Ia) according to any of claims 1 to 7 claim 1 and one or more pharmaceutically acceptable excipients.
- 11. (Currently amended) A method of preparing a compound of formula (Ia) as defined in any of-claims 3 to 7 claim 3 which comprises reaction of the corresponding compound of formula (V):

wherein  $R^1$ ,  $R^2$ , and  $R^3$  are as defined for the compound of formula (Ia) and X is a leaving group selected from chloro, bromo, and iodo, and is preferably chloro; by reaction with the appropriate compound of formula (VI):

wherein the Linker is as defined for the compound of formula (Ia).

- 12. (Original) A compound of formula (V) as defined in claim 11.
- 13. (Currently amended) A kit for the preparation of a radiofluorinated peptide of formula (Ia) according to any of claims 3 to 7 claim 3 comprising:
- (i) a compound of formula (VIa)

wherein L is a leaving group such as p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate,

the Linker is a  $C_{1-30}$  hydrocarbyl group optionally including 1 to 10 heteroatoms; R is hydrogen or a thiol protecting group; and

(ii) an activated peptide of formula (V) as defined in claim 11

- 14. (Currently amended) A kit according to claim 13, comprising:
- (i) a compound of formula (VIb), (VIc), or (VId):

$$L-(CH_2)_p-SR \text{ (VIc)}$$
 $CH_2$ 
 $CH_2$ 
 $CH_2$ 
 $CH_2$ 
 $CH_3$ 
 $CH_4$ 
 $CH_2$ 
 $CH_3$ 
 $CH_4$ 
 $CH_4$ 
 $CH_4$ 
 $CH_5$ 
 $CH_5$ 
 $CH_6$ 
 $C$ 

 $L-(CH_2CH_2O)_n-(CH_2)_m-SR$  (VIb)

n is an integer of 1 to 20;

m is an integer of 1 to 10;

p is an integer of 1 to 20;

q is an integer of 0 to 4;

r is an integer of 1 to 10;

L is a leaving group such as p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate;

L' is a leaving group such as iodo, p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate and when q is 0, L' can be nitro or an iodonium or ammonium salt,

# R is hydrogen or a thiol protecting group; and

## (ii) an activated peptide of formula (V) as defined in claim 11